# Phio Pharmaceuticals Corp.: overview PHIO · Nasdaq · CIK 1533040 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/phio.md) · [Financials](/companies/phio/financials.md) · [Filings](/companies/phio/filings.md) · [Insiders](/companies/phio/insiders.md) Latest reported revenue: [$0](/filings/0001683168-21-001062.md) for Q4 FY2020, three months to 2020-12-31, from the 10-K filed Mar 25, 2021 (XBRL us-gaap:Revenues, accession 0001683168-21-001062). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.54)](/filings/0001683168-24-008120.md) | not reported | [(0.41)](/filings/0001683168-25-003719.md) | [(0.45)](/filings/0001683168-25-006174.md) | not reported | not reported | not reported | not reported | | Free cash flow | $k | [(1,953) d](/filings/0001437749-25-034857.md) | [(1,372) d](/filings/0001437749-26-007078.md) | [(1,277)](/filings/0001437749-26-015604.md) | [(2,543) d](/filings/0001437749-26-026271.md) | [(2,092) d](/filings/0001437749-25-034857.md) | [(2,079) d](/filings/0001437749-26-007078.md) | [(4,003)](/filings/0001437749-26-015604.md) | [(4,035) d](/filings/0001437749-26-026271.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(12.43)](/filings/0001683168-23-001678.md) | [(10.10)](/filings/0001683168-24-002021.md) | [(46.76)](/filings/0001683168-25-002134.md) | [(9.08)](/filings/0001683168-25-002134.md) | not reported | | Free cash flow | $m | [(11.9)](/filings/0001683168-23-001678.md) | [(12.3)](/filings/0001683168-24-002021.md) | [(10.8)](/filings/0001683168-25-002134.md) | [(7.1)](/filings/0001437749-26-007078.md) | [(8.0)](/filings/0001437749-26-007078.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/phio/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $120.7k | 117,755 | | Reduced −1,434 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $117.4k | 114,574 | | Reduced −32,680 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $96.6k | 94,262 | | Added +14,409 | | [NOMURA ASSET MANAGEMENT INTERNATIONAL INC.](/funds/921739.md) | 2026-06-30 | $51.0k | 50,000 | | New +50,000 | | [Cetera Investment Advisers](/funds/1666741.md) | 2026-06-30 | $48.7k | 47,500 | | Added +2,500 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $48.3k | 47,150 | | New +47,150 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $39.1k | 38,169 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $28.5k | 27,768 | | Added +4,010 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $22.0k | 21,501 | | Reduced −10,994 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $18.9k | 18,475 | | Reduced −6,393 | ## Recent filings [All 884 filings](/companies/phio/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 12:41 ET | [8-K](/filings/0001437749-26-032505.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032505 | | 2026-09-28 | 20:01 ET | [8-K](/filings/0001437749-26-031337.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001437749-26-031337 | | 2026-09-14 | 12:59 ET | [8-K](/filings/0001437749-26-030236.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030236 | | 2026-08-14 | 20:04 ET | [DEF 14A](/filings/0001437749-26-027997.md) | Proxy statement, period 2026-09-28 | 0001437749-26-027997 | | 2026-08-06 | 20:16 ET | [8-K](/filings/0001437749-26-026275.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-026275 | | 2026-08-06 | 20:13 ET | [10-Q](/filings/0001437749-26-026271.md) | Quarterly report, period 2026-06-30 | 0001437749-26-026271 | | 2026-07-21 | 11:07 ET | [8-K](/filings/0001437749-26-023916.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-023916 | | 2026-05-07 | 20:23 ET | [10-Q](/filings/0001437749-26-015604.md) | Quarterly report, period 2026-03-31 | 0001437749-26-015604 | | 2026-05-07 | 20:16 ET | [8-K](/filings/0001437749-26-015590.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-015590 | | 2026-04-08 | 20:15 ET | [8-K](/filings/0001437749-26-011761.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001437749-26-011761 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-007078.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1533040 - Tickers: PHIO - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.